Consequences of reductions in hospital readmissions

Gregg C. Fonarow; Clyde W. Yancy

doi:10.1001/jama.2017.14779

Consequences of reductions in hospital readmissions

Gregg C. Fonarow^*, Clyde W. Yancy

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	1933-1934
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	318
Issue number	19
DOIs	https://doi.org/10.1001/jama.2017.14779
State	Published - Nov 21 2017

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2017.14779

Cite this

@article{f83dd9b0dd29403ba9218ad27191cd15,

title = "Consequences of reductions in hospital readmissions",

author = "Fonarow, {Gregg C.} and Yancy, {Clyde W.}",

note = "Funding Information: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fonarow reported serving as a consultant to Amgen, Janssen Pharmaceutical, Medtronic, Novartis, and St Jude Medical; receiving grants to his institution from the National Institutes of Health; and serving on a speakers bureau for Novartis. No other disclosures were reported.",

year = "2017",

month = nov,

day = "21",

doi = "10.1001/jama.2017.14779",

language = "English (US)",

volume = "318",

pages = "1933--1934",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "19",

}

TY - JOUR

T1 - Consequences of reductions in hospital readmissions

AU - Fonarow, Gregg C.

AU - Yancy, Clyde W.

N1 - Funding Information: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fonarow reported serving as a consultant to Amgen, Janssen Pharmaceutical, Medtronic, Novartis, and St Jude Medical; receiving grants to his institution from the National Institutes of Health; and serving on a speakers bureau for Novartis. No other disclosures were reported.

PY - 2017/11/21

Y1 - 2017/11/21

UR - http://www.scopus.com/inward/record.url?scp=85036504749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036504749&partnerID=8YFLogxK

U2 - 10.1001/jama.2017.14779

DO - 10.1001/jama.2017.14779

M3 - Letter

C2 - 29164247

AN - SCOPUS:85036504749

SN - 0098-7484

VL - 318

SP - 1933

EP - 1934

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 19

ER -

Consequences of reductions in hospital readmissions

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this